Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin Maintenance in TP53WT Advanced or Recurrent Endometrial Cancer
2022-502196-31-00Phase 3Completed
- Sponsor
- Kartos Therapeutics
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Navtemadlin maintenance with Placebo maintenance (2 arms). Primary endpoints: Phase 3 dose determination for navtemadlin and Progression-free survival by IRC (Part 2). Started Jul 2023; status: completed.
02
Drugs
navtemadlin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2022-502196-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502196-31-00.